Platelet Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Platelet stocks.

Platelet Stocks Recent News

Date Stock Title
Oct 2 AMGN Weight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right now
Oct 1 SNY Update: Market Chatter: Sanofi Asks Bidders to Revise Offers for Consumer Health Unit
Oct 1 SNY Market Chatter: Sanofi Asks Bidders to Revise Offers for Consumer Health Unit
Oct 1 SNY Sanofi Is Said to Ask Bidders to Revise Consumer Health Offers
Oct 1 AMGN Fresenius Kabi wins FDA approval for Stelara biosimilar Otulfi
Oct 1 AMGN LA LA ANTHONY PARTNERS WITH AMGEN TO SHARE CANDID, BEHIND-THE-SCENES LOOK AT HOW PLAQUE PSORIASIS AFFECTS HER LIFE
Sep 30 AMGN Amgen must face lawsuit claiming it hid $10.7 billion tax bill
Sep 30 SNY Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
Sep 30 AMGN Amgen Inc. (AMGN): Hedge Fund Interest and Strong Pipeline Support Moderate Buy Rating
Sep 30 AMGN Prescription For Dividends: Why Amgen Is More Than Just A Safe Bet
Sep 29 AMGN Institutional investors may overlook Amgen Inc.'s (NASDAQ:AMGN) recent US$7.9b market cap drop as long-term gains remain positive
Sep 28 AMGN Amgen initiated with an Overweight at Cantor Fitzgerald
Sep 28 SNY Regeneron, Sanofi announce Dupixent approval in China for patients with COPD
Sep 27 SNY Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Sep 27 SNY Regeneron/ Sanofi granted FDA label expansion for Dupixent in COPD
Sep 27 SNY Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market following FDA approval
Sep 27 AMGN Regeneron Pharmaceuticals Suffers Worst Month in Two Years After Legal Setback
Sep 27 SNY Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Sep 27 SNY Sanofi, Regeneron get additional Chinese approval for Dupixent
Sep 27 AMGN Cantor highly bullish on Amgen obesity drug, starts coverage at overweight
Platelet

Platelets, also called thrombocytes (from Greek θρόμβος, "clot" and κύτος, "cell"), are a component of blood whose function (along with the coagulation factors) is to react to bleeding from blood vessel injury by clumping, thereby initiating a blood clot. Platelets have no cell nucleus: they are fragments of cytoplasm that are derived from the megakaryocytes of the bone marrow, and then enter the circulation. Circulating unactivated platelets are biconvex discoid (lens-shaped) structures, 2–3 µm in greatest diameter. Platelets are found only in mammals, whereas in other animals (e.g. birds, amphibians) thrombocytes circulate as intact mononuclear cells.

On a stained blood smear, platelets appear as dark purple spots, about 20% the diameter of red blood cells. The smear is used to examine platelets for size, shape, qualitative number, and clumping. The ratio of platelets to red blood cells in a healthy adult ranges from 1:10 to 1:20.
One major function of platelets is to contribute to hemostasis: the process of stopping bleeding at the site of interrupted endothelium. They gather at the site and unless the interruption is physically too large, they plug the hole. First, platelets attach to substances outside the interrupted endothelium: adhesion. Second, they change shape, turn on receptors and secrete chemical messengers: activation. Third, they connect to each other through receptor bridges: aggregation. Formation of this platelet plug (primary hemostasis) is associated with activation of the coagulation cascade with resultant fibrin deposition and linking (secondary hemostasis). These processes may overlap: the spectrum is from a predominantly platelet plug, or "white clot" to a predominantly fibrin, or "red clot" or the more typical mixture. Some would add the subsequent retraction and platelet inhibition as fourth and fifth steps to the completion of the process and still others a sixth step wound repair. Platelets also participate in both innate and adaptive intravascular immune responses.
Low platelet concentration is called thrombocytopenia, and is due to either decreased production or increased destruction. Elevated platelet concentration is called thrombocytosis, and is either congenital, reactive (to cytokines), or due to unregulated production: one of the myeloproliferative neoplasms or certain other myeloid neoplasms. A disorder of platelet function is a thrombocytopathy.
Normal platelets can respond to an abnormality on the vessel wall rather than to hemorrhage, resulting in inappropriate platelet adhesion/activation and thrombosis: the formation of a clot within an intact vessel. This type of thrombosis arises by mechanisms different than those of a normal clot: namely, extending the fibrin of venous thrombosis; extending an unstable or ruptured arterial plaque, causing arterial thrombosis; and microcirculatory thrombosis. An arterial thrombus may partially obstruct blood flow, causing downstream ischemia, or may completely obstruct it, causing downstream tissue death.

Browse All Tags